ArticleActa biomaterialia2019
Cartilage penetrating cationic peptide carriers for applications in drug delivery to avascular negatively charged tissues.
Article in Acta biomaterialia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 120 citations in OpenAlex.
- Hierarchical Nanorocket for spatially coordinated regulation of glycosaminoglycan deposition and metabolism in cartilage.Bioactive materials · 2027Article
- Nanoimmunomodulation for cartilage repair in osteoarthritis: reprogramming the inflammatory joint microenvironment.International journal of pharmaceutics: X · 2026Review
- Protein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis.Journal of drug delivery science and technology · 2026Article
- Peptide-based targeted drug delivery strategies for osteoarthritis treatment.npj biomedical innovations · 2026Review
- Engineered cationic Interleukin-1 receptor antagonist outperforms anakinra at joint retention and preventing IL-1-induced cartilage inflammation.Osteoarthritis and cartilage · 2026Article
- A disease-severity-responsive nanoparticle enables potent ghrelin messenger RNA therapy in osteoarthritis.Nature nanotechnology · 2026Article
- Fine-Tuning Positive-Surface-Charge Carbon Dots for High-Efficiency and Low-Cytotoxicity Gene Delivery.Nanomaterials (Basel, Switzerland) · 2026Article
- Nanotherapeutic Strategies for Osteoarthritis: Targeting Aging, Metabolism and Inflammation.International journal of nanomedicine · 2026Review
- Diabetes-Related Metabolic Osteoarthritis: Advanced Glycation-Collagen Axis, Cartilage Stiffening, and Biomaterials-Based Therapeutic Strategies.International journal of nanomedicine · 2026Review
- What's next for osteoarthritis gene therapy?Frontiers in bioengineering and biotechnology · 2026Review
- Precision-targeted nanodelivery systems for intra-articular treatment of knee osteoarthritis: recent breakthroughs and translational challenges.Frontiers in bioengineering and biotechnology · 2026Review
- A self-assembled nano micelle-exosome with high selectivity and penetrability achieves precise intracartilage lipid delivery.Science advances · 2025Article
- An experimental-computational approach for measuring charged solute diffusivity through human synovium.Journal of biomechanics · 2025Article
- Spatial charge-hydrophobicity configuration modulates cationic peptide transport in cartilage.Biophysical journal · 2025Article
- Cationic Peptoids for Systemic In Vivo Cartilage-Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- High-mobility network hydrogel microsphere system to combat chondrocyte senescence for enhanced cartilage repair and regeneration.Materials today. Bio · 2025Article
- Cartilage-targeting exosomes for delivery of receptor antagonist of interleukin-1 in osteoarthritis treatment.Osteoarthritis and cartilage · 2025Article
- Multiscale characterization of ultrasmall fluorescent core-shell silica nanoparticles in cartilage and synovial joints reveals rapid cartilage penetration and sustained joint residence.Acta biomaterialia · 2025Article
- Cartilage targeting cationic peptide carriers display deep cartilage penetration and retention in a rabbit model of post-traumatic osteoarthritis.Osteoarthritis and cartilage · 2025Article
- Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Drug delivery to avascular, negatively charged tissues like cartilage remains a challenge. The constant turnover of synovial fluid results in short residence time of administered drugs in the joint space and the dense negatively charged matrix of cartilage hinders their diffusive transport. Drugs are, therefore, unable to reach their cell and matrix targets in sufficient doses, and fail to elicit relevant biological response, which has led to unsuccessful clinical trials. The high negative fixed charge density (FCD) of cartilage, however, can be used to convert cartilage from a barrier to drug entry into a depot by making drugs positively charged. Here we design cartilage penetrating and binding cationic peptide carriers (CPCs) with varying net charge, spatial distribution and hydrophobicity to deliver large-sized therapeutics and investigate their electro-diffusive transport in healthy and arthritic cartilage. We showed that CPC uptake increased with increasing net charge up to +14 but dropped as charge increased further due to stronger binding interactions that hindered CPC penetrability and uptake showing that weak-reversible binding is key to enable their penetration through full tissue thickness. Even after 90% GAG depletion, while CPC +14 uptake reduced by over 50% but still had a significantly high value of 148× showing that intra-tissue long-range charge-based binding is further stabilized by short-range H-bond and hydrophobic interactions. The work presents an approach for rational design of cationic carriers based on tissue FCD and properties of macromolecules to be delivered. These design rules can be extended to drug delivery for other avascular, negatively charged tissues. STATEMENT OF SIGNIFICANCE: Osteoarthritis (OA) remains an untreatable disease partly due to short joint residence time of drugs and a lack of delivery methods that can effectively target the dense, avascular, highly negatively charged cartilage tissue. In this study, we designed cartilage penetrating and binding cationic peptide carriers (CPCs) that, due to their optimal charge provide adequate electrical driving force to rapidly transport OA drugs into cartilage and reach their cell and matrix targets in therapeutic doses before drugs exit the joint space. This way cartilage is converted from being a barrier to drug entry into a drug depot that can provide sustained drug release for several weeks. This study also investigates synergistic effects of short-range H-bond and hydrophobic interactions in combination with long-range electrostatic interactions on intra-cartilage solute transport. The work provides rules for rational design of cartilage penetrating charge-based carriers depending on the net charge of tissue (normal versus arthritic), macromolecule to be delivered and whether the application is in drug delivery or tissue imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.